Generic Medicine Info
Indications and Dosage
Acute migraine attacks
Adult: 2.5 mg to be taken after onset, followed by 2.5 mg after 2 hr if required, taken only if migraine recurs after an initial response. Patient not responding to initial dose should not take 2nd dose for the same attack. Max: 5 mg daily.
Hepatic Impairment
Severe: Contraindicated.
May be taken with or without food. Take on an empty stomach for fast relief.
Known or suspected ischaemic heart disease (e.g. angina pectoris, MI, silent ischaemia), coronary vasospasm (e.g. Prinzmetal variant angina), uncontrolled HTN, other serious underlying CV disease, cerebrovascular syndromes (e.g. stroke syndrome, TIA), peripheral vascular disease, or ischaemic bowel disease. Severe hepatic impairment. Concomitant admin w/ ergotamine, its derivatives or other 5-HT1 receptor agonists.
Special Precautions
Patients at risk of coronary artery disease (e.g. hypercholesterolaemia, heavy smokers, obesity, DM, family history of coronary artery disease, menopause, male >40 yr). Not indicated for the management of hemiplegic, basilar or ophthalmoplegic migraine. Mild to moderate hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Dizziness, fatigue, headache, paraesthesia, flushing, dry mouth, abdominal pain, sweating, visual disturbances, hot or cold sensation, skeletal pain, dyspepsia, chest pain, somnolence and nausea.
Potentially Fatal: Cardiac rhythm disturbances (e.g. ventricular tachycardia or fibrillation), acute MI, cerebral or subarachnoid haemorrhage and stroke, serotonin syndrome.
Patient Counseling Information
This drug may cause somnolence, if affected, do not drive or operate machinery.
Monitoring Parameters
Periodic CV evaluation for patients w/ risk factors for coronary artery disease who are receiving intermittent long-term therapy.
Drug Interactions
Potential risk of serotonin syndrome or HTN w/ MAOIs, TCAs, serotonin and norepinephrine reuptake inhibitors (SNRIs) or SSRIs. Increased blood concentrations by fluvoxamine, a potent CYP1A2 inhibitor.
Potentially Fatal: Additive vasospastic effects when used concomitantly w/ ergot alkaloids (e.g. ergotamine, dihydroergotamine, methysergide) and other 5-HT1 receptor agonists.
Food Interaction
Food may delay time to peak plasma concentrations by approx 1 hr. Increased risk of serotonin syndrome w/ St John's wort.
Description: Frovatriptan is a selective agonist for serotonin (5-HT1B and 5-HT1D receptors) in cranial arteries. It causes vasoconstriction and reduces sterile inflammation associated w/ antidromic neuronal transmission correlating w/ relief of migraine.
Absorption: Food may delay time to peak plasma concentrations. Bioavailability: Approx 20% (male); 30% (female). Time to peak plasma concentration: 2-4 hr.
Distribution: Distributed into cellular fraction of blood, principally erythrocytes (approx. 60%, reversibly bound). Plasma protein binding: 15%.
Metabolism: Undergoes hepatic metabolism mainly by CYP1A2 isoenzyme.
Excretion: Via faeces (62%) and urine (approx. 32%). Plasma elimination half-life: Approx 26 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Frovatriptan, CID=77992, (accessed on Jan. 21, 2020)

Store at 25°C. Protect from moisture.
MIMS Class
Antimigraine Preparations
ATC Classification
N02CC07 - frovatriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.
Anon. Frovatriptan. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 14/03/2016.

Buckingham R (ed). Frovatriptan. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 14/03/2016.

Joint Formulary Committee. Frovatriptan. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 14/03/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Frovatriptan Succinate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 14/03/2016.

Disclaimer: This information is independently developed by MIMS based on Frovatriptan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in